MedTrace Logo

Interventricular Delay of Lumax HF-T for Heart Failure

NCT00508391 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2010-01-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to demonstrate that the safety and efficacy of the Lumax HF-T with optimized interventricular delay biventricular pacing (OPT) is non-inferior to the Lumax HF-T with simultaneous biventricular pacing (SIM) in patients with heart failure requiring cardiac resynchronization therapy.

Conditions

  • Congestive Heart Failure

Interventions

DEVICE

Optimized interventricular delay biventricular pacing

Lumax HF-T with optimized interventricular delay biventricular pacing

Sponsors & Collaborators

  • Biotronik, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2008-12-31
Completion
2009-08-31

Countries

  • United States
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00508391 on ClinicalTrials.gov